GlassScriptPhysician profile
Zeyad Sako
NPI 1588016448
$9,784.23
in general payments reported to CMS, 2019-2025
27 companies · $4,539 in 2025
The $4,539 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $426 · 2021: $1,244 · 2022: $1,472 · 2023: $662 · 2024: $1,331 · 2025: $4,539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,506 · Food and Beverage: $1,839 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,506.00 |
| Food and Beverage | $1,838.57 |
| Education | $188.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $2,112.78 | 2024-2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $2,040.00 | 2025 | Fruzaqla |
| Incyte Corporation | $740.47 | 2021-2025 | Zynyz, Pemazyre |
| Astrazeneca Pharmaceuticals LP | $672.73 | 2021-2025 | Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $591.84 | 2019-2025 | Opdivo |
| Genzyme Corporation | $571.73 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $448.54 | 2021-2024 | Libtayo |
| Sanofi-Aventis U.S. LLC | $280.98 | 2020-2024 | |
| Genentech USA, INC. | $205.21 | 2020 | |
| Celgene Corporation | $192.30 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $177.97 | 2024 | Tazverik, Onivyde |
| Lilly USA, LLC | $147.29 | 2021 | |
| Sirtex Medical INC | $141.02 | 2022 | |
| Rigel Pharmaceuticals, INC. | $125.13 | 2022 | |
| Stemline Therapeutics INC. | $124.99 | 2023 | Orserdu |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $124.99 | 2021 | |
| Abbvie INC. | $123.97 | 2022-2024 | |
| Jazz Pharmaceuticals INC. | $121.92 | 2020 | |
| Novocure INC. | $120.88 | 2023 | Optune |
| Exelixis INC. | $116.37 | 2021 | |
| Sobi, INC | $112.63 | 2022 | |
| Karyopharm Therapeutics INC. | $102.83 | 2023 | Xpovio |
| Beone Medicines USA, INC. | $102.00 | 2025 | Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $99.90 | 2022 | |
| Alexion Pharmaceuticals, INC. | $99.00 | 2019 | |
| Progenics Pharmaceuticals, INC. | $68.67 | 2023 | Pylarify |
| Merck Sharp & Dohme LLC | $18.09 | 2024 | Keytruda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zeyad Sako listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.